Skip to content

Phase 3 study to evaluate the efficacy and safety of KK8398 in patients with achondroplasia (AOBA study)

A Multicenter, Open-label, Single-arm, Phase 3 Study of KK8398 (Infigratinib) in Patients with Achondroplasia (AOBA study)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2031240562
Enrollment
6
Registered
2024-12-16
Start date
2025-04-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achondroplasia

Interventions

After obtaining written consent, patients with achondroplasia will have their previous treatment(s) washed out if necessary, and then begin treatment with KK8398.

Sponsors

Sato Yu
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients who are between 2.5 and 17.5 years old of age at the time of provisional registration. Patients who meet certain criteria in terms of Tanner stage and bone age. 2) Patients who have been diagnosed with achondroplasia through genetic testing.

Exclusion criteria

Exclusion criteria: 1) Patients who meet the criteria for a certain height determined by age and gender in the "Growth Chart for Patients with Achondroplasia" at the time of the pre-registration examination. 2) Patients who have received treatment with r-hGH or a CNP analogat within a certain period prior to the pre-enrollment examination. 3) Patients who have had previous osteotomy or who are scheduled to undergo osteotomy or epiphyseal growth inhibition during the study period. Epiphyseal growth inhibition in which the plate was removed more than 26 weeks prior to the pre-registration examination will not be excluded if the patient has completely healed without sequelae, based on the judgment of the investigator or sub-investigator.

Design outcomes

Primary

MeasureTime frame
Change from Baseline in annualized height velocity

Secondary

MeasureTime frame
Change from Baseline at each evaluation point in annualized height velocity

Contacts

Public ContactClinical trial information contact

Kyowa Kirin Co., Ltd.

clinical.info.jp@kyowakirin.com+81-3-5205-7200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026